NOT KNOWN FACTUAL STATEMENTS ABOUT PHENOBARBITAL

Upon initiation or discontinuation of guselkumab in patients that are obtaining concomitant CYP450 substrates, specially These with a narrow therapeutic index, consider monitoring for therapeutic effect.Contraindicated. The therapeutic effect of elbasvir/grazoprevir may be diminished if coadministered with strong CYP3A inducers and it is therefore